MedTrace Logo

Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes

NCT05653518 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-02-25

No results posted yet for this study

Summary

This study will examine the potential cardiovascular effect(s) of artificial pancreas (AP) technology in patients with type 1 diabetes. AP technology is a system of devices that closely mimics the glucose-regulating function of a healthy human pancreas. It includes an insulin pump and a continuous glucose monitor (CGM). In this study, the investigators will research whether improvements in blood glucose levels and blood glucose variability will in turn decrease biomarkers of inflammation and endothelial dysfunction while improving cardiovascular function.

Conditions

Interventions

DEVICE

Tandem t:slim X2 with Control-IQ Technology

FDA approved Tandem t:slim insulin pump with Control-IQ Technology and the Dexcom G6 CGM

DEVICE

Sensor augmented pump (SAP) therapy

Sensor augmented pump (SAP) therapy that includes the use of a study CGM and the participant's personal insulin pump

Sponsors & Collaborators

  • University of Virginia

    lead OTHER

Principal Investigators

  • William B Horton, MD · University of Virginia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-09
Primary Completion
2027-03-30
Completion
2027-03-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05653518 on ClinicalTrials.gov